Alveris Molina
Pulmonary Disease · Jackson Heights, NYNPI 1386605566
Payments from drug & device makers
Across 1,181 payments — averaging $20.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$4K
- AbbVie$3K
- Boehringer Ingelheim$2K
- Novo Nordisk$2K
- Lilly USA, LLC$1K
- Amarin Pharma, Inc.$1K
- plus $11K from 52 others
What the payments were for
- Food & beverage$23,78499%
- Education$1551%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$23,938 in reported general payments places this provider in the 85th percentile of 1,115 pulmonary disease providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 326 | $329,241 |
| VascepaIcosapent Ethyl | 538 | $298,358 |
| OfevNintedanib Esylate | 22 | $274,297 |
| JardianceEmpagliflozin | 187 | $185,355 |
| JanuviaSitagliptin Phosphate | 185 | $175,924 |
| EliquisApixaban | 103 | $104,966 |
| LinzessLinaclotide | 111 | $95,657 |
| TrulicityDulaglutide | 58 | $93,711 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 85 | $81,028 |
| Diclofenac Potassium | 44 | $69,064 |
| XareltoRivaroxaban | 85 | $67,154 |
| ProliaDenosumab | 39 | $64,046 |
| JanumetSitagliptin Phos/Metformin Hcl | 70 | $62,572 |
| Tresiba Flextouch U-200Insulin Degludec | 67 | $58,655 |
| OzempicSemaglutide | 34 | $45,971 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Jardiance, Tradjenta, Synjardy | $2,280 | $495,381254 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Brilinta | $3,539 | $374,563383 claims |
| MerckJanuvia, Janumet | $1,046 | $238,496255 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Shingrix | $910 | $112,244161 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $1,177 | $111,64474 claims |
| PfizerEliquis | $808 | $104,966103 claims |
| AbbVieLinzess | $2,743 | $95,657111 claims |
| Novo NordiskOzempic, Rybelsus | $2,062 | $80,34450 claims |
| Johnson & JohnsonXarelto | $718 | $67,15485 claims |
| AmgenProlia | $1,120 | $64,04639 claims |
| NovartisEntresto | $416 | $45,12032 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance | $1,107 | $14,35420 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,115 pulmonary disease providers in New York.
Other pulmonary disease in Jackson Heights
- Linda RogersNew York$7.1M
- Maria PadillaNew York$3.6M
- R WhiteRochester$3.1M
- Juan WisniveskyNew York$3M
- Bushra MinaNew York$2.5M
- Robert KanerNew York$2.3M
- Negin HajizadehGreenport$2M
- Doreen Addrizzo-HarrisNew York$1.9M
- Sherif El BayadiSyracuse$1.9M
- Daniel LachantRochester$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.